Rami Manochakian, Thoracic Medical Oncologist at Mayo Clinic, shared a post on X:
“Hot Off the Press!
BIG NEWS press release by AstraZeneca.
ADRIATIC phase 3 trial of Durvalumab vs Placebo after concurrent chemoradiotherapy in patients with limited-stage Small Cell Lung Cancer met dual primary endpoints of increased OS and PFS.”
Additional information.
Source: Rami Manochakian/X